导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.85% | 4045/4773 |
| 近一周 | -2.84% | 4322/5465 |
| 近一月 | -2.41% | 1647/5421 |
| 近一季 | 1.23% | 754/5231 |
| 近半年 | -11.06% | 3727/4920 |
| 近一年 | -18.44% | 3892/4394 |
| 近两年 | 6.23% | 2825/2954 |
| 近三年 | -11.43% | 2048/2253 |
| 成立以来 | 18.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.56% 4237/4961 |
-11.00% 4225/5312 |
- - |
- - |
| 2025 | 0.54% 3258/4813 |
-1.01% 2535/3635 |
-3.22% 3417/4076 |
10.45% 3288/4524 |
-4.99% 3505/4813 |
| 2024 | 8.43% 1554/3463 |
3.63% 532/2808 |
-6.36% 1922/3014 |
18.73% 946/3129 |
-5.89% 2604/3463 |
| 2023 | -11.86% 1429/2656 |
1.64% 1536/2280 |
-6.87% 1730/2385 |
-1.43% 519/2515 |
-5.53% 1388/2655 |
| 2022 | -16.23% 462/2207 |
-19.44% 1460/1919 |
17.73% 118/2016 |
-12.51% 714/2113 |
0.96% 1416/2208 |
| 2021 | -10.03% 1090/1822 |
-2.64% 684/1255 |
1.50% 1050/1330 |
-12.14% 1292/1466 |
3.63% 410/1822 |
| 2020 | 69.95% 72/1250 |
-11.75% 851/1028 |
27.06% 134/1067 |
23.82% 27/1164 |
22.41% 44/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝中证消费龙头指数(LOF)A VS. 长安沪深300非周期A(740101) |